AI-Enabled Drug Discovery and Clinical Trials Market Report 2023-2033

AI-Enabled Drug Discovery and Clinical Trials Market Report 2023-2033

The AI-Enabled Drug Discovery and Clinical Trials Market Report 2023-2033: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Growing Awareness of AI applications in Healthcare is Boosting the Market Growth

With the rise of AI applications in healthcare services, people’s awareness and acceptance of AI-enabled solutions have grown. More pharmaceutical companies are, therefore, seeking to incorporate these solutions into their drug discovery and clinical trial processes. AI-based drug delivery solutions are becoming increasingly popular in the pharmaceutical industry. These solutions involve using artificial intelligence technologies to develop more efficient and effective drug delivery methods. The use of AI in drug delivery has the potential to transform the industry by reducing costs, improving drug efficacy and safety, and providing better patient outcomes.

The market for AI-based drug delivery solutions is expected to grow in the coming years, with a number of companies already offering or developing such solutions. Some of the key players in this market include:

Novartis - Novartis is one of the leading players in the AI-based drug delivery market, with a focus on developing smart inhalers to treat respiratory diseases.

Medtronic - Medtronic is a medical devices company that is building an AI-based drug delivery platform to improve the delivery of insulin for diabetic patients.

Insilico Medicine - Insilico Medicine is a drug discovery company that is using AI to develop new drugs and drug delivery methods.

Johnson & Johnson - Johnson & Johnson is using AI to develop personalized drug delivery solutions, including smart drug-infused contact lenses and implantable drug delivery devices.

GSK - GSK is using AI to develop inhalers that can adjust the dosage based on the patient's breathing pattern.

As the competition between market players intensifies, companies are investing heavily in research and development to stay ahead of the curve. This is driving innovation and pushing the boundaries of what is possible in the drug delivery industry. In the future, AI-based drug delivery solutions are likely to become increasingly sophisticated, personalized, and targeted, improving patient outcomes and transforming the pharmaceutical industry.

Lack of Skilled Personnel to Hinder the Market Growth

Patient safety is a significant challenge during the drug discovery phase, as activities involving the interpretation of drug effects and anticipation of potential side effects can pose a major constraint on the market. Additionally, the lack of skilled personnel and inadequate datasets for drug discovery and development are crucial factors that may impact market growth. The implementation of AI systems in drug discovery requires companies to possess expertise in system design, management, and implementation. Given the complexity of AI, personnel working with these systems need to have a deep understanding of technologies such as machine learning, deep learning, and other aspects of artificial intelligence. Integrating AI technologies into existing systems to replicate human brain behaviour necessitates substantial data processing. AI/ML development is being restricted owing to lack of professional standards and certifications.

What Questions Should You Ask before Buying a Market Research Report?

How is the AI-enabled drug discovery and clinical trials market evolving?

What is driving and restraining the AI-enabled drug discovery and clinical trials market?

How will each AI-enabled drug discovery and clinical trials submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2033?

How will the market shares for each AI-enabled drug discovery and clinical trials submarket develop from 2023 to 2033?

What will be the main driver for the overall market from 2023 to 2033?

Will leading AI-enabled drug discovery and clinical trials markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?

How will the market shares of the national markets change by 2033 and which geographical region will lead the market in 2033?

Who are the leading players and what are their prospects over the forecast period?

What are the AI-enabled drug discovery and clinical trials projects for these leading companies?

How will the industry evolve during the period between 2023 and 2033? What are the implications of AI-enabled drug discovery and clinical trials projects taking place now and over the next 10 years?

Is there a greater need for product commercialisation to further scale the AI-enabled drug discovery and clinical trials market?

Where is the AI-enabled drug discovery and clinical trials market heading and how can you ensure you are at the forefront of the market?

What are the best investment options for new product and service lines?

What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the AI-enabled drug discovery and clinical trials market today, and over the next 10 years:

Our 267-page report provides 102 tables and 151 charts/graphs exclusively to you.

The report highlights key lucrative areas in the industry so you can target them – NOW.

It contains in-depth analysis of global, regional and national sales and growth.

It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the AI-enabled drug discovery and clinical trials market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2033 and other analyses reveal commercial prospects

In addition to revenue forecasting to 2033, our new study provides you with recent results, growth rates, and market shares.

You will find original analyses, with business outlooks and developments.

Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising AI-enabled drug discovery and clinical trials prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.

Segments Covered in the Report

Component Outlook

Services

Software

Application

Clinical Trials

Drug Design

Data Aggregation and Analysis

Drug Characterization

Biomarker Research

Others

Therapeutic Area

Oncology

Cardiovascular Diseases

Infectious Diseases

Neurodegenerative Diseases

Metabolic Diseases

Others

End-user

Pharmaceutical & Biopharmaceutical Companies

Contract Research Organizations (CROs)

Others

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 18 leading national markets:

North America

U.S.

Canada

Europe

Germany

UK

France

Spain

Italy

Russia

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Argentina

Rest of Latin America

MEA

GCC

South Africa

Rest of MEA

The report also includes profiles and for some of the leading companies in the AI-Enabled Drug Discovery and Clinical Trials Market, 2023 to 2033, with a focus on this segment of these companies’ operations.

Leading companies and the potential for market growth

AbbVie Inc.

Exscientia

GNS Healthcare

IBM Watson

Merck & Co., Inc.

Novartis AG

PathAI

Saama Technologies

Unlearn.AI, Inc.

Overall world revenue for AI-Enabled Drug Discovery and Clinical Trials Market, 2023 to 2033 in terms of value the market will surpass US$2,156.8 million in 2023, our work calculates. We predict strong revenue growth through to 2033. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the AI-Enabled Drug Discovery and Clinical Trials Market, 2023 to 2033 report help you?

In summary, our 260+ page report provides you with the following knowledge:

Revenue forecasts to 2033 for AI-Enabled Drug Discovery and Clinical Trials Market, 2023 to 2033 Market, with forecasts for component, application, therapeutic area, and end-user, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.

Revenue forecasts to 2033 for five regional and 18 key national markets – See forecasts for the AI-Enabled Drug Discovery and Clinical Trials Market, 2023 to 2033 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.

Prospects for established firms and those seeking to enter the market – including company profiles for 9 of the major companies involved in the AI-Enabled Drug Discovery and Clinical Trials Market, 2023 to 2033.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Our study is for everybody needing commercial analyses for the AI-Enabled Drug Discovery and Clinical Trials Market, 2023 to 2033, market-leading companies. You will find data, trends and predictions.

Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher..

The publisher is using a password system to access single user and team licenses. Single user (non-printable) and team licenses expire after 12 month period. In the case of team license purchases, the publisher requires all email addresses for the licensed users prior to fulfilment.